Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 25
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana|||0000-0003-4124-9788
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Pato, Miguel L.|||0000-0001-8840-7259
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Cardus, Oriol|||0000-0002-5446-5423
  • Salsench, Sergi V.|||0000-0002-4390-6887
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa|||0000-0003-4324-3371
  • Gutiérrez, Norma C.
  • Prósper, Felipe
  • Agirre, Xabier|||0000-0002-6558-9560
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Esteller, M|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Writers, readers and erasers of RNA modifications in cancer

  • Esteve-Puig, R.|||0000-0003-0547-1752
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Esteller, M.|||0000-0003-4490-6093
Although cancer was originally considered a disease driven only by genetic mutations, it has now been proven that it is also an epigenetic disease driven by DNA hypermethylation-associated silencing of tumor suppressor genes and aberrant histone modifications. Very recently, a third component has emerged: the so-called epitranscriptome understood as the chemical modifications of RNA that regulate and alter the activity of RNA molecules. In this regard, the study of genetic and epigenetic disruption of the RNA-modifying proteins is gaining momentum in advancing our understanding of cancer biology. Furthermore, the development of epitranscriptomic anticancer drugs could lead to new promising and unexpected therapeutic strategies for oncology in the coming years.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Disruption of the RNA modifications that target the ribosome translation machinery in human cancer

  • Janin, Maxime|||0000-0003-1013-4128
  • Coll-Sanmartin, Laia
  • Esteller, M.|||0000-0003-4490-6093
Genetic and epigenetic changes deregulate RNA and protein expression in cancer cells. In this regard, tumors exhibit an abnormal proteome in comparison to the corresponding normal tissues. Translation control is a crucial step in the regulation of gene expression regulation under normal and pathological conditions that ultimately determines cellular fate. In this context, evidence shows that transfer and ribosomal RNA (tRNA and rRNA) modifications affect the efficacy and fidelity of translation. The number of RNA modifications increases with the complexity of organisms, suggesting an evolutionary diversification of the possibilities for fine-tuning the functions of coding and non-coding RNAs. In this review, we focus on alterations of modifications of transfer and ribosomal RNA that affect translation in human cancer. This variation in the RNA modification status can be the result of altered modifier expression (writers, readers or erasers), but also due to components of the machineries (C/D or H/ACA boxes) or alterations of proteins involved in modifier expression. Broadening our understanding of the mechanisms by which site-specific modifications modulate ribosome activity in the context of tumorigenesis will enable us to enrich our knowledge about how ribosomes can influence cell fate and form the basis of new therapeutic opportunities.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The DNA methylation landscape of human cancer organoids available at the American type culture collection

  • Joshi, Ricky S.|||0000-0003-4463-0453
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Piñeyro, David|||0000-0001-5633-3339
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Arribas, Carles
  • Esteller, M.|||0000-0003-4490-6093
One caveat in cancer research is the dependence of certain experimental systems that might not really reflect the properties of the primary tumours. The recent irruption of 3D cultured cells termed organoids could render a better representation of the original tumour sample. However, every laboratory has its own protocol and tissue-provider to establish these cancer models, preventing further dissemination and validation of the obtained data. To address this problem, the Human Cancer Models Initiative (HCMI) has selected the American Type Culture Collection (ATCC) to make available organoid models to the scientific community. In this regard, no epigenetic information is available for these samples and, overall, the DNA methylation profiles of human cancer organoids are largely unknown. Herein, we provide the DNA methylation landscape of 25 human cancer organoids available at the ATCC using a microarray that interrogates more than 850,000 CpG sites. We observed that the studied organoids retain the epigenetic setting of their original primary cancer type; that exhibit a DNA methylation landscape characteristic of transformed tissues excluding an overgrowth of normal-matched cells; and that are closer to the DNA methylation profiles of the corresponding primary tumours than to established 2D cell lines. Most importantly, the obtained DNA methylation results are freely available to everyone for further data mining. Thus, our findings support from the epigenetic standpoint that the ATCC human cancer organoids recapitulate many of the features of the disorder in the patient and are excellent tools to be shared among investigators for further tumour biology research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Contribution of Epigenetics to Cancer Immunotherapy

  • Villanueva, Lorea|||0000-0003-1858-7076
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Esteller, M.|||0000-0003-4490-6093
Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer management. Nonetheless, not all patients benefit from such therapies because they fail to achieve complete responses, suffer frequent relapses, or develop potentially life-threatening toxicities. Epigenomic signatures in immune and cancer cells appear to be accurate and promising predictors of patient outcomes with immunotherapy. In addition, combined treatments with epigenetic drugs can exploit the dynamic nature of epigenetic changes to potentially modulate responses to immunotherapy. Candidate epigenetic biomarkers may provide a rationale for patient stratification and precision medicine, thus maximizing the chances of treatment success while minimizing unwanted effects. We present a comprehensive up-to-date view of potential epigenetic biomarkers in immunotherapy and discuss their advantages over other indicators.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the transfer RNA-modifying enzyme TYW2 induces ribosome frameshifts in colon cancer

  • Rosselló-Tortella, Margalida|||0000-0003-4610-7981
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Sakaguchi, Y.
  • Miyauchi, K.
  • Davalos, Veronica|||0000-0003-4077-5137
  • Setien, Fernando|||0000-0002-4061-4635
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Piñeyro, David|||0000-0001-5633-3339
  • Martínez-Gómez, Jesús|||0000-0002-7770-073X
  • Guil, Sonia|||0000-0002-2257-3331
  • Joshi, Ricky S.|||0000-0003-4463-0453
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Suzuki, Tsutomu
  • Esteller, M.|||0000-0003-4490-6093
Transfer RNA (tRNA) activity is tightly regulated to provide a physiological protein translation, and tRNA chemical modifications control its function in a complex with ribosomes and messenger RNAs (mRNAs). In this regard, the correct hypermodification of position G37 of phenylalanine-tRNA, adjacent to the anticodon, is critical to prevent ribosome frameshifting events. Here we report that the tRNA-yW Synthesizing Protein 2 (TYW2) undergoes promoter hypermethylation-associated transcriptional silencing in human cancer, particularly in colorectal tumors. The epigenetic loss of TYW2 induces guanosine hypomodification in phenylalanine-tRNA, an increase in -1 ribosome frameshift events, and down-regulation of transcripts by mRNA decay, such as of the key cancer gene ROBO1. Importantly, TYW2 epigenetic inactivation is linked to poor overall survival in patients with early-stage colorectal cancer, a finding that could be related to the observed acquisition of enhanced migration properties and epithelial-to-mesenchymal features in the colon cancer cells that harbor TYW2 DNA methylation-associated loss. These findings provide an illustrative example of how epigenetic changes can modify the epitranscriptome and further support a role for tRNA modifications in cancer biology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The DNA methylation landscape of hematological malignancies, an update

  • Blecua, Pedro|||0000-0002-1012-0300
  • Martínez-Verbo, Laura|||0000-0003-0817-3056
  • Esteller, M.|||0000-0003-4490-6093
The rapid advances in high-throughput sequencing technologies have made it more evident that epigenetic modifications orchestrate a plethora of complex biological processes. During the last decade, we have gained significant knowledge about a wide range of epigenetic changes that crucially contribute to some of the most aggressive forms of leukemia, lymphoma, and myelodysplastic syndromes. DNA methylation is a key epigenetic player in the abnormal initiation, development, and progression of these malignancies, often acting in synergy with other epigenetic alterations. It also contributes to the acquisition of drug resistance. In this review, we summarize the role of DNA methylation in hematological malignancies described in the current literature. We discuss in detail the dual role of DNA methylation in normal and aberrant hematopoiesis, as well as the involvement of this type of epigenetic change in other aspects of the disease. Finally, we present a comprehensive overview of the main clinical implications, including a discussion of the therapeutic strategies that regulate or reverse aberrant DNA methylation patterns in hematological malignancies, including their combination with (chemo)immunotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer

  • Piqué, Laia
  • Martinez de Paz, A.
  • Piñeyro, David|||0000-0001-5633-3339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Setien, F.
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Sigurdsson, S.|||0000-0002-5284-0058
  • Jonasson, J. G.
  • Villanueva, Alberto|||0000-0001-5164-0006
  • Vidal, A.
  • Davalos, Veronica|||0000-0003-4077-5137
  • Esteller, M.|||0000-0003-4490-6093
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma, implications for biomarker-driven clinical trials

  • Montal, Robert
  • Andreu-Oller, Carmen|||0000-0001-7405-9134
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Esteban-Fabró, Roger
  • Moran, S.|||0000-0003-4192-8983
  • Montironi, Carla|||0000-0002-1453-2193
  • Moeini, Agrin
  • Pinyol, Roser|||0000-0002-0288-6314
  • Peix, Judit
  • Cabellos, Laia
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Sia, Daniela|||0000-0002-9000-611X
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
  • Esteller, M.|||0000-0003-4490-6093
  • Llovet, Josep M.|||0000-0003-0547-2667
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single cell cancer epigenetics

  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Esteller, M|||0000-0003-4490-6093
Bulk sequencing methodologies have allowed us to make great progress in cancer research. Unfortunately, these techniques lack the resolution to fully unravel the epigenetic mechanisms that govern tumor heterogeneity. Consequently, many novel single cell-sequencing methodologies have been developed over the past decade, allowing us to explore the epigenetic components that regulate different aspects of cancer heterogeneity, namely: clonal heterogeneity, tumor microenvironment (TME), spatial organization, intratumoral differentiation programs, metastasis, and resistance mechanisms. In this review, we explore the different sequencing techniques that enable researchers to study different aspects of epigenetics (DNA methylation, chromatin accessibility, histone modifications, DNA-protein interactions, and chromatin 3D architecture) at the single cell level, their potential applications in cancer, and their current technical limitations
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute lymphoblastic leukemia necessitates GSH-dependent ferroptosis defenses to overcome FSP1-epigenetic silencing

  • Pontel, Lucas B.|||0000-0001-8384-3422
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Morellato, Agustín E.
  • Santos, Juliana|||0000-0003-4148-9570
  • Roué, Gaël|||0000-0003-0245-2257
  • Esteller, M|||0000-0003-4490-6093
Ferroptosis is a form of cell death triggered by phospholipid hydroperoxides (PLOOH) generated from the iron-dependent oxidation of polyunsaturated fatty acids (PUFAs). To prevent ferroptosis, cells rely on the antioxidant glutathione (GSH), which serves as cofactor of the glutathione peroxidase 4 (GPX4) for the neutralization of PLOOHs. Some cancer cells can also limit ferroptosis through a GSH-independent axis, centered mainly on the ferroptosis suppressor protein 1 (FSP1). The significance of these two anti-ferroptosis pathways is still poorly understood in cancers from hematopoietic origin. Here, we report that blood-derived cancer cells are selectively sensitive to compounds that block the GSH-dependent anti-ferroptosis axis. In T- and B- acute lymphoblastic leukemia (ALL) cell lines and patient biopsies, the promoter of the gene coding for FSP1 is hypermethylated, silencing the expression of FSP1 and creating a selective dependency on GSH-centered anti-ferroptosis defenses. In-trans expression of FSP1 increases the resistance of leukemic cells to compounds targeting the GSH-dependent anti-ferroptosis pathway. FSP1 over-expression also favors ALL-tumor growth in an in vivo chick chorioallantoic membrane (CAM) model. Hence, our results reveal a metabolic vulnerability of ALL that might be of therapeutic interest
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

DNA methylation-associated dysregulation of transfer RNA expression in human cancer

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The challenge of diagnosing constitutional mismatch repair deficiency syndrome in brain malignancies from young individuals

  • Carrato, Cristina|||0000-0002-1953-8287
  • Sanz, Carolina|||0009-0001-9228-755X
  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Pineda, Marta|||0000-0002-5403-5845
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Dámaso, Estela|||0000-0002-9650-7791
  • Esteller, M|||0000-0003-4490-6093
  • Musulén, Eva|||0000-0002-9667-6464
Biallelic germline mismatch repair (MMR) gene (MLH1, MSH2, MSH6, and PMS2) mutations are an extremely rare event that causes constitutional mismatch repair deficiency (CMMRD) syndrome. CMMRD is underdiagnosed and often debuts with pediatric malignant brain tumors. A high degree of clinical awareness of the CMMRD phenotype is needed to identify new cases. Immunohistochemical (IHC) assessment of MMR protein expression and analysis of microsatellite instability (MSI) are the first tools with which to initiate the study of this syndrome in solid malignancies. MMR IHC shows a hallmark pattern with absence of staining in both neoplastic and non-neoplastic cells for the biallelic mutated gene. However, MSI often fails in brain malignancies. The aim of this report is to draw attention to the peculiar IHC profile that characterizes CMMRD syndrome and to review the difficulties in reaching an accurate diagnosis by describing the case of two siblings with biallelic MSH6 germline mutations and brain tumors. Given the difficulties involved in early diagnosis of CMMRD we propose the use of the IHC of MMR proteins in all malignant brain tumors diagnosed in individuals younger than 25 years-old to facilitate the diagnosis of CMMRD and to select those neoplasms that will benefit from immunotherapy treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gene amplification-associated overexpression of the selenoprotein trna enzyme trit1 confers sensitivity to arsenic trioxide in small-cell lung cancer

  • Coll-Sanmartin, Laia
  • Davalos, Veronica|||0000-0003-4077-5137
  • Piñeyro, David|||0000-0001-5633-3339
  • Rosselló-Tortella, Margalida|||0000-0003-4610-7981
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Setien, Fernando|||0000-0002-4061-4635
  • Villanueva, Alberto|||0000-0001-5164-0006
  • Granada, Isabel|||0000-0002-4275-0104
  • Ruiz-Xiviller, Neus
  • Kotter, Annika
  • Helm, Mark|||0000-0002-0154-0928
  • Yokota, Jun|||0000-0001-6010-6294
  • Kawabata-Iwakawa, Reika|||0000-0002-3504-1393
  • Kohno, Takashi|||0000-0002-5371-706X
  • Esteller, M.|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary

  • Blecua, Pedro|||0000-0002-1012-0300
  • Davalos, Veronica|||0000-0003-4077-5137
  • De Villasante, Izar|||0000-0001-7325-0631
  • Merkel, Angelika|||0000-0001-5164-6803
  • Musulén, Eva|||0000-0002-9667-6464
  • Coll-Sanmartin, Laia
  • Esteller, M|||0000-0003-4490-6093
High-throughput genomic technologies are increasingly used in personalized cancer medicine. However, computational tools to maximize the use of scarce tissues combining distinct molecular layers are needed. Here we present a refined strategy, based on the R-package 'conumee', to better predict somatic copy number alterations (SCNA) from deoxyribonucleic acid (DNA) methylation arrays. Our approach, termed hereafter as 'conumee-KCN', improves SCNA prediction by incorporating tumor purity and dynamic thresholding. We trained our algorithm using paired DNA methylation and SNP Array 6.0 data from The Cancer Genome Atlas samples and confirmed its performance in cancer cell lines. Most importantly, the application of our approach in cancers of unknown primary identified amplified potentially actionable targets that were experimentally validated by Fluorescence in situ hybridization and immunostaining, reaching 100% specificity and 93.3% sensitivity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Experimental and Bioinformatic Approaches to Studying DNA Methylation in Cancer

  • Merkel, Angelika|||0000-0001-5164-6803
  • Esteller, M|||0000-0003-4490-6093
DNA methylation is an essential epigenetic mark. Alterations of normal DNA methylation are a defining feature of cancer. Here, we review experimental and bioinformatic approaches to showcase the breadth and depth of information that this epigenetic mark provides for cancer research. First, we describe classical approaches for interrogating bulk DNA from cell populations as well as more recently developed approaches for single cells and multi-Omics. Second, we focus on the computational analysis from primary data processing to the identification of unique methylation signatures. Additionally, we discuss challenges such as sparse data and cellular heterogeneity. https://doi.org/10.13039/5011000110335https://doi.org/10.13039/5011000110333https://doi.org/10.13039/5011000110336https://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033_https://doi.org/10.13039/501100011033_https://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033 $h ttps://doi.org/10.13039/501100011033ahttps://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033Ahttps://doi.org/10.13039/501100011033ghttps://doi.org/10.13039/501100011033ehttps://doi.org/10.13039/501100011033nhttps://doi.org/10.13039/501100011033chttps://doi.org/10.13039/501100011033ihttps://doi.org/10.13039/501100011033ahttps://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033Ehttps://doi.org/10.13039/501100011033shttps://doi.org/10.13039/501100011033thttps://doi.org/10.13039/501100011033ahttps://doi.org/10.13039/501100011033thttps://doi.org/10.13039/501100011033ahttps://doi.org/10.13039/501100011033lhttps://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033dhttps://doi.org/10.13039/501100011033ehttps://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033Ihttps://doi.org/10.13039/501100011033nhttps://doi.org/10.13039/501100011033vhttps://doi.org/10.13039/501100011033ehttps://doi.org/10.13039/501100011033shttps://doi.org/10.13039/501100011033thttps://doi.org/10.13039/501100011033ihttps://doi.org/10.13039/501100011033ghttps://doi.org/10.13039/501100011033ahttps://doi.org/10.13039/501100011033chttps://doi.org/10.13039/501100011033ihttps://doi.org/10.13039/501100011033óhttps://doi.org/10.13039/501100011033nhttps://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033 $h ttps://doi.org/10.13039/501100011033dhttps://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033 $h ttps://doi.org/10.13039/501100011033fhttps://doi.org/10.13039/501100011033 https://doi.org/10.13039/501100011033Rhttps://doi.org/10.13039/501100011033Thttps://doi.org/10.13039/501100011033Ihttps://doi.org/10.13039/5011000110332https://doi.org/10.13039/5011000110330https://doi.org/10.13039/5011000110331https://doi.org/10.13039/5011000110338https://doi.org/10.13039/501100011033-https://doi.org/10.13039/5011000110330https://doi.org/10.13039/5011000110339https://doi.org/10.13039/5011000110334https://doi.org/10.13039/5011000110330https://doi.org/10.13039/5011000110334https://doi.org/10.13039/5011000110339https://doi.org/10.13039/501100011033-https://doi.org/10.13039/501100011033Bhttps://doi.org/10.13039/501100011033-https://doi.org/10.13039/501100011033Ihttps://doi.org/10.13039/5011000110330https://doi.org/10.13039/5011000110330https://doi.org/10.13039/501100011033
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Look-alike humans identified by facial recognition algorithms show genetic similarities

  • Joshi, Ricky S.|||0000-0003-4463-0453
  • Rigau, M.
  • García-Prieto, Carlos A|||0000-0001-5021-6916
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Piñeyro, David|||0000-0001-5633-3339
  • Moran, S|||0000-0003-4192-8983
  • Davalos, Veronica|||0000-0003-4077-5137
  • Carrión, P.
  • Ferrando-Bernal, Manuel|||0000-0003-4129-6242
  • Olalde, I.
  • Lalueza-Fox, Carles|||0000-0002-1730-5914
  • Navarro, Arcadi|||0000-0003-2162-8246
  • Fernández-Tena, C.
  • Aspandi, D.|||0000-0002-6653-3470
  • Sukno, F.M.
  • Binefa i Valls, Xavier|||0000-0002-4324-9952
  • Valencia, A.
  • Esteller, M|||0000-0003-4490-6093
The human face is one of the most visible features of our unique identity as individuals. Interestingly, monozygotic twins share almost identical facial traits and the same DNA sequence but could exhibit differences in other biometrical parameters. The expansion of the world wide web and the possibility to exchange pictures of humans across the planet has increased the number of people identified online as virtual twins or doubles that are not family related. Herein, we have characterized in detail a set of "look-alike" humans, defined by facial recognition algorithms, for their multiomics landscape. We report that these individuals share similar genotypes and differ in their DNA methylation and microbiome landscape. These results not only provide insights about the genetics that determine our face but also might have implications for the establishment of other human anthropometric properties and even personality characteristics.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer

  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Esteller, M|||0000-0003-4490-6093
Adoptive cell therapy (ACT) constitutes a major breakthrough in cancer management that has expanded in the past years due to impressive results showing durable and even curative responses for some patients with hematological malignancies. ACT leverages antigen specificity and cytotoxic mechanisms of the immune system, particularly relying on the patient's T lymphocytes to target and eliminate malignant cells. This personalized therapeutic approach exemplifies the success of the joint effort of basic, translational, and clinical researchers that has turned the patient's immune system into a great ally in the search for a cancer cure. ACTs are constantly improving to reach a maximum beneficial clinical response. Despite being very promising therapeutic options for certain types of cancers, mainly melanoma and hematological malignancies, these individualized treatments still present several shortcomings, including elevated costs, technical challenges, management of adverse side effects, and a limited population of responder patients. Thus, it is crucial to discover and develop reliable and robust biomarkers to specifically and sensitively pinpoint the patients that will benefit the most from ACT as well as those at higher risk of developing potentially serious toxicities. Although unique readouts of infused cell therapy success have not yet been identified, certain characteristics from the adoptive cells, the tumor, and/or the tumor microenvironment have been recognized to predict patients' outcome on ACT. Here, we comment on the importance of biomarkers to predict ACT chances of success to maximize efficacy of treatments and increase patients' survival.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy

  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Davalos, Veronica|||0000-0003-4077-5137
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Mata, Caterina|||0000-0001-9403-7434
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Roué, Gaël|||0000-0003-0245-2257
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Acha, Pamela|||0000-0002-4528-1219
  • Manzanares Mileo, Ana|||0000-0003-4125-4675
  • Tobiasson, Magnus|||0000-0002-3633-5852
  • Hellström-Lindberg, Eva|||0000-0002-7839-3743
  • Sole, F|||0000-0002-3251-2161
  • Esteller, M|||0000-0003-4490-6093
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we have leveraged the unprecedented analytical power of single-cell technologies to simultaneously map the genome and immunoproteome of MDS samples throughout clinical evolution. We were able to chart the architecture and evolution of molecular clones in precious paired bone marrow MDS samples at diagnosis and post-treatment to show that a combined imbalance of specific cell lineages with diverse mutational profiles is associated with the clinical response of MDS patients to hypomethylating therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Towards a druggable epitranscriptome, Compounds that target RNA modifications in cancer

  • Berdasco, Maria|||0000-0002-6750-0400
  • Esteller, M|||0000-0003-4490-6093
Epitranscriptomics is an exciting emerging area that studies biochemical modifications of RNA. The field has been opened up by the technical efforts of the last decade to characterize and quantify RNA modifications, and this has led to a map of post-transcriptional RNA marks in normal cell fate and development. However, the scientific interest has been fuelled by the discovery of aberrant epitranscriptomes associated with human diseases, mainly cancer. The challenge is now to see whether epitrancriptomics offers mechanisms that can be effectively targeted by low MW compounds and are thus druggable. In this review, we will describe the principal RNA modifications (with a focus on mRNA), summarize the latest scientific evidence of their dysregulation in cancer and provide an overview of the state-of-the-art drug discovery to target the epitranscriptome. Finally, we will discuss the principal challenges in the field of chemical biology and drug development to increase the potential of targeted-RNA for clinical benefit. LINKED ARTICLES: This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.12/issuetoc.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of a DNA methylation microarray for 285,000 CpG sites in the mouse genome

  • García-Prieto, Carlos A|||0000-0001-5021-6916
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Musulén, Eva|||0000-0002-9667-6464
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Vazquez Prat, Berta Nieves|||0000-0002-8164-3926
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Esteller, M|||0000-0003-4490-6093
Mouse has been extensively used as a model organism in many studies to characterize biological pathways and drug effects and to mimic human diseases. Similar DNA sequences between both species facilitate these types of experiments. However, much less is known about the mouse epigenome, particularly for DNA methylation. Progress in delivering mouse DNA methylomes has been slow due to the currently available time-consuming and expensive methodologies. Following the great acceptance of the human DNA methylation microarrays, we have herein validated a newly developed DNA methylation microarray (Infinium Mouse Methylation BeadChip) that interrogates 280,754 unique CpG sites within the mouse genome. The CpGs included in the platform cover CpG Islands, shores, shelves and open sea sequences, and loci surrounding transcription start sites and gene bodies. From a functional standpoint, mouse ENCODE representative DNase hypersensitivity sites (rDHSs) and candidate cis-Regulatory Elements (cCREs) are also included. Herein, we show that the profiled mouse DNA methylation microarray provides reliable values among technical replicates; matched results from fresh frozen versus formalin-fixed samples; detects hemimethylated X-chromosome and imprinted CpG sites; and is able to determine CpG methylation changes in mouse cell lines treated with a DNA demethylating agent or upon genetic disruption of a DNA methyltransferase. Most important, using unsupervised hierarchical clustering and t-SNE approaches, the platform is able to classify all types of normal mouse tissues and organs. These data underscore the great features of the assessed microarray to obtain comprehensive DNA methylation profiles of the mouse genome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genetic and epigenetic defects of the RNA modification machinery in cancer

  • Orsolic, Ines
  • Carrier, Arnaud|||0000-0002-9200-7685
  • Esteller, M|||0000-0003-4490-6093
Cancer was initially considered to be an exclusively genetic disease, but an interplay of dysregulated genetic and epigenetic mechanisms is now known to contribute to the cancer phenotype. More recently, chemical modifications of RNA molecules - the so-called epitranscriptome - have been found to regulate various aspects of RNA function and homeostasis. Specific enzymes, known as RNA-modifying proteins (RMPs), are responsible for depositing, removing, and reading chemical modifications in RNA. Intensive investigations in the epitranscriptomic field in recent years, in conjunction with great technological advances, have revealed the critical role of RNA modifications in regulating numerous cellular pathways. Furthermore, growing evidence has revealed that RNA modification machinery is often altered in human cancers, highlighting the enormous potential of RMPs as pharmacological targets or diagnostic markers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Remodeling of the m6A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies

  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Davalos, Veronica|||0000-0003-4077-5137
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Juan, Manel|||0000-0002-3064-1648
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Delgado, Julia
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Del Bufalo, Francesca
  • Locatelli, Franco|||0000-0002-7976-3654
  • Quintarelli, Concetta
  • Sinibaldi, Matilde
  • Soler, Marta|||0000-0002-6656-957X
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Urdinguio, Rocío G.|||0000-0003-2736-5758
  • Fernandez, Agustin F.
  • Fraga, Mario|||0000-0001-8450-2603
  • Bar, Diana
  • Meir, Agustín
  • Itzhaki, Orit
  • Besser, MichalJ.
  • Avigdor, Abraham
  • Jacoby, Elad
  • Esteller, M.|||0000-0003-4490-6093
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. The increasingly recognized relevance of epigenetic changes in cancer immunology prompted us to determine the impact of the DNA methylation profiles of CART19 cells on the clinical course. Methods: We recruited 114 patients with B-cell malignancies, comprising 77 patients with acute lymphoblastic leukemia and 37 patients with non-Hodgkin lymphoma who were treated with CART19 cells. Using a comprehensive DNA methylation microarray, we determined the epigenomic changes that occur in the patient T cells upon transduction of the CAR vector. The effects of the identified DNA methylation sites on clinical response, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, event-free survival, and overall survival were assessed. All statistical tests were 2-sided. Results: We identified 984 genomic sites with differential DNA methylation between CAR-untransduced and CAR-transduced T cells before infusion into the patient. Eighteen of these distinct epigenetic loci were associated with complete response (CR), adjusting by multiple testing. Using the sites linked to CR, an epigenetic signature, referred to hereafter as the EPICART signature, was established in the initial discovery cohort (n = 79), which was associated with CR (Fisher exact test, P <. 001) and enhanced event-free survival (hazard ratio [HR] = 0.36; 95% confidence interval [CI] = 0.19 to 0.70; P =. 002; log-rank P =. 003) and overall survival (HR = 0.45; 95% CI = 0.20 to 0.99; P =. 047; log-rank P =. 04;). Most important, the EPICART profile maintained its clinical course predictive value in the validation cohort (n = 35), where it was associated with CR (Fisher exact test, P <. 001) and enhanced overall survival (HR = 0.31; 95% CI = 0.11 to 0.84; P =. 02; log-rank P =. 02). Conclusions: We show that the DNA methylation landscape of patient CART19 cells influences the efficacy of the cellular immunotherapy treatment in patients with B-cell malignancy.